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Background: An ameloblastoma is a benign odontogenic neoplasm with aggressive behaviour and high
recurrence rates. The increased expression of matrix metalloproteinases (MMPs) has been reported in
ameloblastomas. In the present study, we hypothesised that epigenetic alterations may regulate MMP expression in
ameloblastomas.
Methods: We investigated the methylation status of the genes MMP-2 and MMP-9 in addition to mRNA
transcription and protein expression in ameloblastomas. Methylation analysis was performed by both
methylation-specific polymerase chain reaction (MSP-PCR) and restriction enzyme digestion to evaluate the
methylation profile of MMP-2 and MMP-9 in 12 ameloblastoma samples and 12 healthy gingiva fragments, which
were included as controls. Furthermore, we investigated the transcription levels of the genes by quantitative
reverse-transcription PCR (qRT-PCR). Zymography was performed to verify protein expression in ameloblastomas.
Results: The ameloblastomas showed a high frequency of unmethylated MMP-2 and MMP-9, whereas the healthy
gingival samples presented a sharp prevalence of methylated MMPs. Higher expression levels of MMP-9 were found
in ameloblastomas compared to healthy gingiva. However, no significant differences in the MMP-2 mRNA
expression between groups was found. All ameloblastomas showed positive expression of MMP-2 and MMP-9
proteins.
Conclusions: Our findings suggest that expression of MMP-9 is increased in ameloblastomas and is possibly
modulated by unmethylation of the gene.
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EpigeneticBackground
An ameloblastoma is a benign odontogenic tumour that
exhibits a high recurrence risk, aggressive behaviour and
local invasiveness [1]. Histologically, an ameloblastoma
consists of epithelial strands or islands of ameloblastic
epithelium. The peripheral cells are columnar, while the
cells lying more centrally are fusiform to polyhedral and
are loosely connected to each other [1].
Different studies have demonstrated genetic alterations
in odontogenic tumours [2-4], but few studies have* Correspondence: rsgomez@ufmg.br
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reproduction in any medium, provided the oranalysed epigenetic events in these tumours [5-7]. Methy-
lation is an epigenetic alteration that plays an important
role in controlling gene activity, embryonic development,
and genomic imprinting. It has been associated with gene
silencing by transcriptional inactivation [8]. DNA methyla-
tion or hypomethylation of the p16, p21 and LINE-1 genes
was reported in ameloblastomas by our group and others
[5,9,10], but the significance of this data remains to be
determined.
Matrix metalloproteinases (MMPs) are zinc-dependent
enzymes that are important in extracellular matrix remod-
elling and are associated with tumour growth and invasion
through collagen matrix degradation [11]. The invasive
characteristic of ameloblastomas has been associated with
the expression of genes related to bone turnover andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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RANKL and its receptor, MMP and TIMP [12-17]. As
MMPs may be regulated by DNA methylation in malig-
nant neoplasms [18,19], such phenomenon might be im-
portant in ameloblastoma pathogenesis and should be
investigated. Therefore, the purpose of this study was to
investigate the association between MMP-2 and MMP-9
methylation and their mRNA transcription and protein
expression in ameloblastomas.Methods
Patients and tissue samples
Twelve fresh ameloblastoma specimens were collected
during surgical care in the Department of Oral Surgery
and Pathology, Universidade Federal de Minas Gerais,
Brazil. These samples comprised eleven solid-multicystic
follicular ameloblastomas and one unicystic case. Diag-
noses were confirmed by histopathologic analysis based
on the World Health Organization classification of
histological typing of odontogenic tumours [1]. Other
clinical data are shown in Table 1. Twelve fragments of
healthy gingival samples with no clinical evidence of in-
flammation were collected during third molar extrac-
tions and used as controls. The samples were obtained
following informed consent and with the approval of the
Universidade Federal de Minas Gerais Ethics Committee
(reference number 266/11).DNA isolation and methylation analysis of MMP-2 and
MMP-9
Genomic DNA was isolated from the tissue samples using
a Qiagen DNeasy Tissue Kit (Qiagen Inc., Valencia, CA,
USA) according to the manufacturer’s instructions. Meth-
Primer software [20] was used to search CpG islands and
sparse CG dinucleotides. Distinct methods are suggested
to analyse methylation profiles according to the presenceTable 1 Distribution of subjects according to gender, age
and anatomic site
Parameters Ameloblastoma (n= 12) Healthy gingiva (n = 12)
Gender
Male 05 (41.7%) 07 (58.3%)
Female 07 (58.3%) 05 (41.7%)
Age (years)
Variation 8-51 19-28
Mean± SD 31.0 ± 14.6 25.4 ± 5.3
Anatomic Sites
Mandible
anterior region 01 (8.3%) 0
posterior region 11 (91.7%) 4 (33.3%)
Maxilla 0 8 (66.7%)of CpG islands or sparse CG dinucleotides located in the
promoter region or in exons near to that region [21].
To assess the MMP-2 gene CpG island methylation, gen-
omic DNA was modified by sodium bisulfite as described
previously [6] and subsequently amplified with primer sets
designed to specifically recognise methylated (F 5’-GCG
GTTATACGTATCGAGTTAGC-3’ and R 5’-ACTCTTTA
TCCGTTTTAAAAACGAC-3’; 205 bp) and unmethylated
DNA (F 5’-GGTGGTTATATGTATTGAGTTAGTGA-3’
and R 5’-ACTCTTTATCCATTTTAAAAACAAC-3’
206 bp). Bisulfite-treated unmethylated DNA from (periph-
eral blood mononuclear cells) cells was used as a positive
control for unmethylated amplification of the MMP-2 gene.
Methylation-induced DNA of same cells by the MSssI
methylase enzyme (New England Biolabs, Beverly, USA)
was used as positive control for methylated amplification.
The methylation-sensitive restriction enzymes HhaI
and AciI (New England BioLabs, Beverly, MA, USA)
were used to assess the methylation of CG dinucleotides
in the MMP-9 promoter, including the CG sites located
at positions -35, -185, -223, -233, as described previously
[21]. Restriction enzymes cleave DNA at unmethylated
CG sites, but they are unable to cut methylated cyto-
sines. Analysis using a bioinformatics web site (http://
www.restrictionmapper.org) showed that the HhaI en-
zyme cleaves the restriction site at position -35 and that
the other sites are cleaved by AciI. The CG dinucleotides
analysed in this study are located close to the transcrip-
tion start of the MMP-9 gene. Two hundred nanograms
of genomic DNA was digested separately with each of
the restriction enzymes HhaI and AciI according to
manufacturer's protocol to cleave the specific regions
containing CG sites (New England BioLabs, Beverly,
MA, USA). Digestion was followed by PCR amplification
(primers: F 5’-GCTTCATCCCCCTCCCTCC-3’, R 5’-AG
CACCAGGACCAGGGGC-3’; 369 bp). PCR products
were subjected to electrophoresis in 6.5% polyacryl-
amide gels. While methylated cytosine produces a band
equivalent to that of control methylated DNA of pla-
centa tissue, the cleavage by restriction enzyme at
unmethylated CpG induces DNA strand breaks, and
thus no band is detected. In each PCR reaction, un-
digested DNA of each sample was also carried out as
controls. Undigested and digested PCR products were
electrophoresed in parallel. Human unmethylated DNA
(Qiagen Inc., Valencia, CA, USA), which is sensitive to
action of the enzyme, was also used as unmethylated
positive control.
RNA extraction and Quantitative Real-time PCR (qRT-PCR)
of MMP-2 and MMP-9
Total RNA was extracted from tissue samples using Trizol
reagent according to the manufacturer’s protocol (Invitro-
gen, Carlsbad, CA, USA). RNA integrity was analysed by
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1 μg of RNA to cDNA was performed using SuperScript
III First-Strand (Invitrogen, Carlsbad, CA, USA) following
the manufacturer’s instructions. Primer sequences were
designed using the PrimerExpress software (v.3, Applied
Biosystems) as follows: MMP-2 (F: 5’-AGCTCCCGG
AAAAGATTGATG-3’; R: 5’-CAGGGTGCTGGCTG
AGTAGAT-3’, 101 bp) and MMP-9 (F: 5’-GAGGTT
CGACGTGAAGGCGCAGAT-3’; R: 5’-CATAGGTCACG
TAGCCCACT TGGT3’, 200 bp). All reactions were run in
duplicate in a StepOne Real time PCR System using the
SYBR-green fluorescence quantification system (Applied
Biosystems, Warrington, UK). The comparative Ct method
was used [22]. Expression levels of the MMP-2 and MMP-
9 genes relative to a calibrator sample (placenta tissue)
were obtained by normalisation to endogenous β-actin.Gelatin zymography
Ameloblastoma protein was extracted and subjected to
electrophoresis under nonreducing conditions on SDS-
polyacrylamide gels copolymerised with 1 mg/ml gelatin
(Sigma Chemical Co, St Louis, MO, USA) as previously
described [23]. After electrophoresis, the gels were
washed in 2.5% Triton-X 100 and incubated for at least
18 h at 37°C in incubation buffer (50 mM Tris–HCl, pH
7.5, containing 5 mM CaCl2, 100 mM NaCl, 0.01% Tri-
ton X-100). Zymographic gels were stained in 0.2% Coo-
massie Brilliant Blue R-250 and de-stained. The gels
were scanned to analyse the bands representative of
MMPs, according to molecular weight. Analysis of pro-
tein expression in healthy gingiva was not performed
due to the scarcity of tissue samples.Statistical analysis
Mann–Whitney tests were used to compare the relative
quantification of MMP-2 and MMP-9 between groups.
Chi-squared or Fisher’s exact were used when appropri-





MMP-9 methylation/restriction site digested by HhaI
Methylated 0 (0.0%)
Unmethylated 12 (100.0
MMP-9 methylation/restriction site digested by AciI
Methylated 01 (8.3%)
Unmethylated 11 (91.7%
* Fisher’s exact test (p < 0.05).software, and probability values <0.05 were considered
statistically significant.
Results
MMP-2 and MMP-9 methylation statuses are shown in
Table 2 and represented in Figure 1. While all healthy
gingival samples showed MMP-2 methylation, approxi-
mately half of ameloblastomas were unmethylated. Simi-
larly, an increased frequency of unmethylated MMP-9 of
specific CG sites digested by HhaI was identified in the
ameloblastomas. Almost all of the ameloblastoma sam-
ples showed an unmethylated profile for MMP-9. No
difference was found in the methylation of CG sites
digested by Acil among the groups studied.
The qRT-PCR results are summarised in Figures 2a
and 2b. Higher expression levels of MMP-9 were found
in ameloblastomas compared to healthy gingiva. How-
ever, significant differences in the MMP-2 mRNA ex-
pression levels were not found.
When we investigated the influence of the methylation
status of both genes on their transcription, no associ-
ation was found between MMP-2 transcription and its
methylation in ameloblastomas (p = 0.319). Almost all of
the tumour samples showed an unmethylated MMP-9
pattern in conjunction with increased mRNA levels. As
most of the ameloblastomas were unmethylated at the
MMP-9 gene, considering all of the restriction sites, it
was not possible to statistically compare the transcrip-
tion of the gene in the cases with or without methylated
sequences.
All of the ameloblastoma samples showed expression
of MMP-2 and MMP-9 proteins, as verified by zymogra-
phy (Figure 3). However, pro-MMP-2 and pro-MMP-9
forms were not identified in ameloblastomas.
Discussion
The underlying molecular pathways associated with the
pathogenesis of ameloblastomas are not well established
yet. Previous investigations have assessed the moleculareloblastoma and healthy gingiva
astoma (n = 12) Healthy gingiva (n = 12) p-value*






Figure 1 Representative figure of the methylation analysis. A: Methylation status of MMP-2 in ameloblastoma. M: PCR products when
amplified by methylated primers (205 bp); U: PCR products when amplified by unmethylated primers (206 bp); +M: positive control for
methylated reaction; +U: positive control for unmethylated reaction. -M and -U: negative controls without DNA. Lines 1 to 3 represent DNA from
ameloblastoma samples. B: Methylation status of MMP-9 in ameloblastoma. DNA samples were digested by the AciI restriction enzyme followed
by PCR, flanking the restriction sites. Absent band indicates unmethylated profile (U) due to DNA cleavage by the restriction enzyme. Presence of
the PCR band represents methylated profile (M) of the MMP-9 gene. +M: methylated positive control; +U: unmethylated positive control; - :
negative control without DNA.
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lelic loss of tumour suppressor genes, deregulation of
the Sonic Hedgehog signalling pathway, and the clonality
of these tumours [3,24,25].
Matrix metalloproteinases are involved in the degradation
of collagen, as well as bone matrix, and have been shown to
play a key role in the local invasiveness of ameloblastoma
cells [15,26]. Overexpression of MMP-2 and MMP-9 was
associated with the infiltrative behaviour of ameloblasto-
mas, as well as that of several malignant neoplasms [17,27].
The suppression of MMP-2 activity was able to inhibit the
invasiveness of ameloblastoma cells in vitro [14,15]. Fur-
thermore, it was suggested that increased expression of
MMP-9 may be involved in the proliferation and invasive
behaviour of ameloblastomas [26].
Some papers, including studies from our research
group, have demonstrated epigenetic alterations inFigure 2 qRT-PCR results of MMP-2 (A) and MMP-9 (B) mRNA transcrip
expression is shown as the mean ± SE. All reactions were normalised to β-
(p < 0.05).odontogenic tumours [5,6,9,10,28]. In the present study,
we hypothesised that methylation may regulate the ex-
pression of MMP-2 and MMP-9 in ameloblastomas. We
also investigated the association between methylation
and the transcription levels of these genes. As most of
the ameloblastoma samples were of the solid follicular
type, we were not able to analyse possible associations
between each clinical or histological type and the mo-
lecular data.
MMPs play an important role in collagen matrix re-
modelling in physiologic and pathologic processes, such
as those found in basal membranes, dental follicle tissue
and tumour metastasis [27,29]. Although MMP-2 is
related to ameloblastoma pathogenesis, it seems to be
constitutively expressed in physiologic tissues and many
cell types and to exhibit characteristics of a housekeep-
ing gene [30-32]. Perhaps this could explain the similartion in ameloblastoma and healthy gingiva. In both analyses, gene
actin and are relative to a calibrator sample. * Mann–Whitney test
Figure 3 Zymography gel electrophoresis representing MMP-2
(72 KDa) and MMP-9 protein (92 KDa) in ameloblastoma. Lines
1 to 7 represent protein extracts from ameloblastoma samples.
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and healthy gingiva. Furthermore, our data suggest that
MMP-2 expression in ameloblastomas may not be
modulated by methylation because the methylation pro-
file for this gene did not correlate with MMP-2 tran-
script levels in this odontogenic tumour.
The ameloblastomas presented an unmethylated pro-
file of MMP-2 and MMP-9 genes compared to gingiva.
Furthermore, along with unmethylated MMP-9, this
tumour showed increased transcription of MMP-9 when
compared to the control group. The important role of
methylation in epigenetic silencing is well established,
particularly through regulatory mechanisms of transcrip-
tion. Accordingly, our data suggest that an unmethylated
profile of the MMP-9 gene in ameloblastomas may be a
permissive event allowing the binding of transcription
factors to DNA, thus favouring MMP-9 gene
transcription.
All of the ameloblastomas showed MMP-9 protein ex-
pression and were mostly unmethylated for MMP-9, so
it was not possible to assess if the transcription of the
gene was correlated with its methylation status. How-
ever, our study suggests that the increased transcription
of MMP-9 in ameloblastomas could possibly be influ-
enced by unmethylation of the gene. The evident protein
expression, identified by zymography, provides add-
itional evidence supporting the possible gene regulation
by unmethylated MMP-9. It is interesting to note that
hypomethylation of the MMP-2 and MMP-9 genes
increases gene expression and contributes to cancer cell
invasiveness and tumourigenesis in malignant neo-
plasms, such as prostate cancer and lymphoma [18,33].
Conclusion
In conclusion, our study provides new insights into the
epigenetic regulation of MMPs in ameloblastomas and
points to the hypomethylation of MMP-9 as a possible
mechanism involved in the increased transcription of
the gene in this tumour. However, functional studies are
needed to better explain the role the methylation ofmatrix metalloproteinases plays in the pathogenesis of
ameloblastoma.
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